Phase-2B / Phase-3 *ETHYL CERVONATE™ is a trademark of Sancilio & Company, Inc.
A New Paradigm in Sickle Cell Disease Treatment for Children through a Proprietary Platform for Enhanced Absorption of Lipophilic Drugs.
Altemia™ is an investigational drug that uses ALT® designed to prevent painful crises in Sickle Cell Disease patients.
Altemia™ Product Benefits
The largest study ever conducted in support that Ethyl Cervonate™ is safe and well tolerated in patients with Sickle Cell Disease
Studies show that Ethyl Cervonate™ helps Sickle Cell patients achieve significant and sustained reduction in painful crises, along with significant improvement in anemia with a reduction in the need for blood transfusions
Children with Sickle Cell Disease who took Ethyl Cervonate™ had fewer absences in school and overall better attendance than children with Sickle Cell Disease who did not take Ethyl Cervonate™